Corylin inhibits osteoclastogenesis and attenuates postmenopausal osteoporosis in mice

doi:10.3969/j.issn.2095-4344.2974

Abstract

Abstract: BACKGROUND: The balance of bone homeostasis is mediated by the osteoclast-related bone resorption and osteoblast-related bone formation. Over-activation of osteoclasts results in a series of bone metabolic diseases including rheumatoid arthritis and osteoporosis. The activation of nuclear factor-κB pathway induced by receptor activator of nuclear factor-κB ligand (RANKL) plays an important role in osteoclastogenesis.
OBJECTIVE: To explore the effect of corylin on RANKL-mediated osteoclastogenesis.
METHODS: RAW264.7 cells were incubated with 0, 1, 2, 4, 8, 16, 32, 64, 128 μmol/L corylin. The cytotoxicity of corylin was detected by cell counting kit-8 assay. RANKL induced the differentiation of RAW264.7 cells into osteoclasts, during which 2, 5, 10 μmol/L corylin was given. The number of osteoclasts was analyzed by TRAP staining after 5 days of intervention and the morphology and function of osteoclasts were analyzed by F-actin staining. Bone resorption assay was conducted after 2 days of intervention. The activation of nuclear factor-κB pathway was detected by western blot at 0, 15, 30, and 60 minutes of intervention. Then in vivo experiments were carried out, and the ovariectomized mice were intraperitoneally given 10 mg/kg twice a week. After 6 weeks of intervention, mouse femurs were taken for morphological analysis.
RESULTS AND CONCLUSION: There was no cytotoxicity of corylin below the concentration of 16 μmol/L. Corylin inhibited osteoclastogenesis in a dose-dependent manner. Corylin inhibited the formation of F-actin and resorption activity of osteoclasts. Corylin inhibited RANKL-mediated nuclear factor-κB pathway. Corylin treatment reduced the bone loss in postmenopausal osteoporosis mice. Overall, corylin inhibits osteoclastogenesis via blocking nuclear factor-κB pathway and attenuates postmenopausal osteoporosis.

Key words: bone, corylin, osteoclast, pathway, osteoporosis, mouse, bone resorption, bone formation

CLC Number:

Li Xiaoqun, Xu Kaihang, Ji Fang. Corylin inhibits osteoclastogenesis and attenuates postmenopausal osteoporosis in mice[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(2): 186-190.

Figures/Tables 6

References

[1] SIMS NA, MARTIN TJ. Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms. Annu Rev Physiol. 2020;82:507-529.
[2] HUANG J, LIN D, WEI Z, et al. Parathyroid Hormone Derivative with Reduced Osteoclastic Activity Promoted Bone Regeneration via Synergistic Bone Remodeling and Angiogenesis. Small. 2020;16(6):e1905876.
[3] HASEGAWA T, KIKUTA J, SUDO T, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol. 2019;20(12):1631-1643.
[4] SIPILÄ S, TÖRMÄKANGAS T, SILLANPÄÄ E, et al. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020 Feb 3. doi: 10.1002/jcsm.12547. [Epub ahead of print]
[5] DE MARTINIS M, SIRUFO MM, GINALDI L. Osteoporosis: Current and emerging therapies targeted to immunological checkpoints. Curr Med Chem. 2019 Jul 30. doi: 10.2174/0929867326666190730113123. [Epub ahead of print]
[6] RUCHLEMER R, AMIT-KOHN M, TVITO A, et al. Bone loss and hematological malignancies in adults: a pilot study. Support Care Cancer. 2018;26(9):3013-3020.
[7] ZEBIC L, PATEL V. Preventing medication-related osteonecrosis of the jaw. BMJ. 2019;365:l1733.
[8] MCCLUNG MR, O’DONOGHUE ML, PAPAPOULOS SE, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019;7(12):899-911.
[9] VELETIC I, MANSHOURI T, MULTANI AS, et al. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood. 2019;133(21):2320-2324.
[10] OIKAWA T, OYAMA M, KOZUKA-HATA H, et al. Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell-cell fusion. J Cell Biol. 2012;197(4):553-568.
[11] MA QL, FANG L, JIANG N, et al. Bone mesenchymal stem cell secretion of sRANKL/OPG/M-CSF in response to macrophage-mediated inflammatory response influences osteogenesis on nanostructured Ti surfaces. Biomaterials. 2018;154:234-247.
[12] KWON OC, CHOI B, LEE EJ, et al. Negative Regulation of Osteoclast Commitment by Intracellular Protein Phosphatase Magnesium-Dependent 1A. Arthritis Rheumatol. 2020;72(5):750-760.
[13] ETHIRAJ P, OTTINGER AM, SINGH T, et al. Proteasome inhibition suppress microgravity elevated RANK signaling during osteoclast differentiation. Cytokine. 2020;125:154821.

[14] LEE NK, CHOI YG, BAIK JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 2005;106(3):852-859.

[15] 林瑞民,王大为,熊志立,等.补骨脂中两个黄酮类成分的高效液相色谱测定[J].中国中药杂志,2002,27(9): 669-671.
[16] KLOTZ LH, MCNEILL IY, KEBABDJIAN M, et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 2013;63(5):927-935.
[17] YU AX, XU ML, YAO P, et al. Corylin, a flavonoid derived from Psoralea Fructus, induces osteoblastic differentiation via estrogen and Wnt/β-catenin signaling pathways. FASEB J. 2020;34(3):4311-4328.
[18] XIN Z, JIN C, CHAO L, et al. A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5. Front Pharmacol. 2018;9:22.
[19] CHEN X, ZHI X, WANG J, et al. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res. 2018;6:34.
[20] CHELLAIAH MA, MOORER MC, MAJUMDAR S, et al. L-Plastin deficiency produces increased trabecular bone due to attenuation of sealing ring formation and osteoclast dysfunction. Bone Res. 2020;8:3.
[21] COLEMAN R, BODY JJ, AAPRO M, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25 Suppl 3:iii124-37.
[22] CAPOZZI A, LELLO S, PONTECORVI A. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab. Gynecol Endocrinol. 2014;30(6):403-408.
[23] XU R, YALLOWITZ A, QIN A, et al. Targeting skeletal endothelium to ameliorate bone loss. Nat Med. 2018;24(6):823-833.
[24] LEUTNER M, MATZHOLD C, BELLACH L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis. 2019;78(12):1706-1711.
[25] RODAN GA, MARTIN TJ. Therapeutic approaches to bone diseases. Science. 2000;289(5484):1508-1514.
[26] 孙燕.中医中药在肿瘤综合治疗中的应用[J].中国中西医结合杂志,1997, 17(6):323-324.
[27] HUANG MY, TU CE, WANG SC, et al. Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia. BMC Complement Altern Med. 2018;18(1):221.
[28] CHEN CY, CHEN CC, SHIEH TM, et al. Corylin Suppresses Hepatocellular Carcinoma Progression via the Inhibition of Epithelial-Mesenchymal Transition, Mediated by Long Noncoding RNA GAS5. Int J Mol Sci. 2018;19(2): E380.
[29] CHEN CC, CHEN CY, UENG SH, et al. Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis. 2018;9(5):543.
[30] CHELLAIAH MA, MA T, MAJUMDAR S. L-plastin phosphorylation regulates the early phase of sealing ring formation by actin bundling process in mouse osteoclasts. Exp Cell Res. 2018;372(1):73-82.
[31] TANG Y, WU X, LEI W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7): 757-765.
[32] CHENG C, WENTWORTH K, SHOBACK DM. New Frontiers in Osteoporosis Therapy. Annu Rev Med. 2020;71:277-288.
[33] SANCAR F. Caution With New Osteoporosis Drug. JAMA. 2019;321(19):1862.
[34] HODSMAN AB, BAUER DC, DEMPSTER DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688-703.
[35] MCCLUNG MR. Clinical utility of anti-sclerostin antibodies. Bone. 2017;96:3-7.
[36] CLINE-SMITH A, AXELBAUM A, SHASHKOVA E, et al. Ovariectomy Activates Chronic Low-Grade Inflammation Mediated by Memory T Cells, Which Promotes Osteoporosis in Mice. J Bone Miner Res. 2020 Jan 29. doi: 10.1002/jbmr.3966. [Epub ahead of print]